Novavax Raises Revenue Forecast on Boost From Vaccine Deals, Shares Soar

Feb 26 (Reuters) - Novavax ⁠raised ⁠its adjusted revenue forecast for ⁠2026 on Thursday, banking on milestone payments from ...

Novavax outlines $230M–$270M 2026 revenue target with new Pfizer partnership and cost reduction strategy

Management provided a 2026 adjusted total revenue target of $230 million to $270 million, including $35 million to $45 million of Nuvaxovid product sales under existing orders, $40 million to $50 ...
Hosted on MSN

Novavax Strengthens Position with Vaccine Approval and Sanofi Partnership

Novavax, Inc. (NASDAQ:NVAX) is one of the 11 Best Short Squeeze Stocks to Buy Now. The company’s non-mRNA COVID-19 vaccine is approved, strengthening its Sanofi partnership. A closeup of a vial of the ...

Novavax, Inc. Q4 2025 Earnings Call Summary

Recognized $625 million in primarily non-cash revenue in 2025 following the resolution of historical APA agreements with ...